SPN Antibody

What is SPN antibody and what does it detect?

SPN antibody recognizes the SPN antigen, which has been identified as the same protein as NuMA (Nuclear Mitotic Apparatus protein). NuMA is a 238 kDa protein present in the nucleus during interphase that translocates to the spindle poles during mitosis . The protein is also known by other names including centrophilin, SP-H, and NuMA-1 . Proper identification of this antibody is crucial as it helps track an essential protein involved in mitotic spindle formation and nuclear architecture.

Why is SPN/NuMA antibody important in cell biology research?

SPN/NuMA antibody is critical for studying mitotic processes because microinjection experiments have demonstrated that the SPN/NuMA antigen plays an essential functional role during mitosis. Studies show that microinjection of the SPN-3 monoclonal antibody into cells causes mitotic arrest and micronuclei formation, indicating the protein's importance in normal cell division . This makes the antibody an invaluable tool for investigating the mechanics of cell division and nuclear organization.

What is the basic structure of the SPN/NuMA protein?

The NuMA protein has a tripartite structure consisting of a long central rod domain flanked by globular end domains . This structure has been directly visualized through electron microscopy studies using recombinant protein fragments expressed in E. coli and purified to homogeneity. Understanding this structure helps researchers interpret antibody binding patterns and protein function during the cell cycle.

What are the common experimental applications for SPN/NuMA antibody?

SPN/NuMA antibodies are commonly used in several experimental techniques:

Researchers should validate the antibody for each specific application as performance can vary significantly between techniques .

How should SPN/NuMA antibody be validated for specific experimental applications?

Validation of SPN/NuMA antibody should follow these methodological steps:

• Application-specific validation: The antibody must be validated for each specific experimental technique (immunofluorescence, Western blot, etc.) as specificity in one application doesn't guarantee specificity in another .

• Rigorous validation methods: The most rigorous validation includes comparison of wildtype versus knockdown/knockout tissues and/or use of a second antibody to a different epitope of the same protein .

• Fixative-specific validation: For immunofluorescence, validation should be performed for each fixative used, as antibody performance can vary significantly .

• Reporting validation: Validation should be clearly reported in publications, either through inclusion in supplementary materials or citation of previous validation studies .

How are epitopes of SPN/NuMA antibodies mapped?

Epitope mapping of SPN/NuMA antibodies has been accomplished using recombinant NuMA fragments . For example, the SPN-3 epitope has been specifically located to residues 255-267 at the C-terminus of the first helical subdomain of the central rod domain . Several crucial residues for antibody binding have been identified through these mapping studies.

More generally, epitope mapping can be performed through:

• Expression of protein fragments and testing antibody binding

• Peptide arrays covering the target protein sequence

• Mutagenesis studies of potential binding sites

• Hydrogen-deuterium exchange mass spectrometry

How can researchers distinguish between different anti-NuMA/SPN antibodies?

Different anti-NuMA antibodies, including anti-NuMA-1 (also known as SPN) and anti-HsEg5, can be distinguished through:

• Indirect immunofluorescence patterns: NuMA-1/SPN antibodies stain interphase cells, whereas HsEg5 antibodies do not .

• Western blotting: Different antibodies show distinct banding patterns based on their specific epitopes .

• Epitope location: Knowing the specific epitope location helps distinguish between different antibodies targeting various regions of the NuMA protein .

Understanding these distinctions is critical when interpreting experimental results and comparing findings across different studies.

What functional insights can be gained from microinjection of SPN-3 antibody?

Microinjection of SPN-3 antibody into cells at different stages of mitosis provides critical insights into NuMA function:

• When injected in prophase, prometaphase, or metaphase, 90%, 78%, and 77% of cells respectively display defective cytokinesis or yield daughter cells with micronuclei .

• In contrast, only 16% of cells injected in anaphase show abnormalities .

This temporal dependency suggests the SPN/NuMA antigen is required primarily during early stages of mitosis rather than later stages. Interestingly, these effects parallel those seen with colcemid and taxol treatments on PtK2 and HeLa cells, suggesting potential mechanistic similarities in how these interventions disrupt mitosis .

How does antibody design impact the specificity and utility of anti-SPN/NuMA antibodies?

Rational antibody design approaches can significantly improve the specificity and utility of antibodies including those targeting NuMA/SPN. Key considerations include:

• Complementary peptide design: Designing peptides complementary to specific disordered epitopes within the target protein and grafting them onto antibody scaffolds .

• Scaffold selection: Using stable antibody scaffolds that tolerate grafting of peptide segments into CDR loops, such as human heavy chain variable (VH) domains that remain soluble and stable without light chain partners .

• Expression and characterization: Ensuring high purity (>95%) and native-like structure through methods such as chromatography and circular dichroism spectroscopy .

• Multiple validation approaches: Using techniques like ELISA to verify binding specificity and affinity of the designed antibodies .

What information should be reported when using SPN/NuMA antibody in research publications?

To ensure reproducibility, publications using SPN/NuMA antibody should report:

• Core antibody information:

  • Name of the antibody (e.g., SPN-3)

  • Company/academic supplier

  • Host species

  • Whether monoclonal or polyclonal

  • Catalogue or clone number

• Experimental details:

  • Application the antibody was used for

  • Species of samples tested

  • Antibody batch number (especially if batch variability is observed)

  • Final antibody concentration or dilution

• Validation information:

  • Evidence of validation for the specific application

  • Reference to validation profiles in public databases

  • New validation data in supplementary materials

A suggested format is: "Mouse anti-SPN/NuMA monoclonal antibody (Company E, catalogue number #1000) was used for immunofluorescence with human cells as validated in (reference Y) and Western blotting in mouse tissue as validated in (figure X)."

How does antibody polyreactivity affect SPN/NuMA antibody experiments and how can it be mitigated?

Antibody polyreactivity—the tendency to bind multiple unrelated antigens—can significantly impact experimental outcomes by creating false positives or background noise. For SPN/NuMA antibodies, this is particularly concerning given their use in detecting specific cellular structures during mitosis.

To assess and mitigate polyreactivity:

• Computational prediction: Machine learning models can predict polyreactivity based on antibody sequence and suggest specific amino acid substitutions to reduce it .

• Experimental testing: Test antibodies against multiple unrelated targets (e.g., lysozyme, dsDNA, ssDNA, insulin, LPS) using direct ELISA assays .

• PSR staining: Use polyspecificity reagent (PSR) staining to evaluate polyreactivity against diverse protein mixtures .

• Position-specific modifications: Implement amino acid substitutions that reduce polyreactivity while maintaining target specificity, noting that contributions to polyreactivity are highly position-dependent .

What is the clinical significance of anti-NuMA/SPN autoantibodies?

Anti-NuMA (SPN) autoantibodies have been detected in patients with various connective tissue diseases (CTDs):

• Prevalence: The prevalence of anti-NuMA pattern in antinuclear antibody (ANA) testing ranges from 0.047% in Chinese studies to 0.77% in European cohorts, indicating geographic and racial/ethnic variations .

• Disease associations: In one study, 60% of NuMA-positive patients had a connective tissue disease, distributed as follows:

  • Sjögren's syndrome: 21.5%

  • Rheumatoid arthritis: 16%

  • Systemic lupus erythematosus: 14%

  • Antiphospholipid syndrome: 9.2%

  • Spondyloarthropathies: 4.6%

• Specificity characteristics: Anti-NuMA tends to show the highest titers of ANA among mitotic spindle apparatus patterns and behaves similarly to a monospecific antibody, sometimes being the only positive marker (in 81.5% of patients) .

How are anti-NuMA/SPN antibodies detected in clinical laboratories?

Anti-NuMA/SPN antibodies are typically detected through:

• Indirect immunofluorescence (IIF): Using HEp-2 cells as substrate, which is considered the gold standard for ANA testing . The NuMA pattern shows a distinctive staining of the nucleus during interphase and spindle poles during mitosis.

• Pattern recognition: Anti-NuMA antibodies create a specific pattern classified as a mitotic spindle apparatus (MSA) pattern, specifically NuMA/MSA-1 .

• Titer determination: Serial dilutions starting at 1:80 are typically used, with NuMA pattern showing relatively high titers (mean 320, range 80-2560) .

• Confirmation testing: Western blotting can be used to confirm specificity and distinguish between NuMA-1 and HsEg5 antibodies .

How can SPN/NuMA antibodies be used to study cell cycle regulation?

SPN/NuMA antibodies offer several approaches to studying cell cycle regulation:

• Temporal protein dynamics: By using antibodies in time-course experiments, researchers can track the redistribution of NuMA from the nucleus to the spindle poles during mitosis .

• Functional perturbation studies: Microinjection of SPN-3 antibody at specific cell cycle stages helps determine when NuMA function is critical (primarily early rather than later stages of mitosis) .

• Protein interaction networks: Immunoprecipitation with SPN/NuMA antibodies followed by mass spectrometry can identify cell cycle-specific interaction partners.

• Phosphorylation state analysis: Using phospho-specific SPN/NuMA antibodies helps track regulatory modifications during cell cycle progression.

What are the considerations for using SPN/NuMA antibodies in immunohistochemistry of tissue samples?

When using SPN/NuMA antibodies for immunohistochemistry:

• Fixation methods: Different fixation protocols can significantly affect antibody accessibility to the NuMA epitope. Optimization may be required for specific tissue types.

• Epitope retrieval: Antigen retrieval methods (heat-induced or enzymatic) should be optimized for NuMA detection in formalin-fixed paraffin-embedded tissues.

• Detection systems: Amplification systems (e.g., tyramide signal amplification) may enhance detection sensitivity, particularly for low-abundance nuclear proteins.

• Controls: Both positive controls (tissues known to express NuMA) and negative controls (antibody omission, non-specific IgG) are essential for result interpretation.

• Batch-to-batch variability: Antibody lot testing is recommended as polyclonal antibodies in particular may show significant batch variation .

How can researchers address non-specific binding of SPN/NuMA antibodies?

Non-specific binding can be addressed through:

• Blocking optimization: Test different blocking agents (BSA, normal serum, commercial blockers) to reduce background.

• Antibody dilution: Perform titration experiments to determine the optimal antibody concentration that maximizes specific signal while minimizing background.

• Secondary antibody selection: Choose highly cross-adsorbed secondary antibodies to reduce non-specific binding.

• Sample preparation: Ensure thorough washing between steps and consider pre-adsorption with irrelevant antigens if cross-reactivity is suspected.

• Polyreactivity assessment: Evaluate antibody polyreactivity through computational prediction or experimental testing against unrelated targets .

What approaches can verify the specificity of a SPN/NuMA antibody?

To verify SPN/NuMA antibody specificity:

• Genetic approaches:

  • Test antibody against NuMA-knockout or knockdown cells

  • Compare staining patterns in wildtype versus genetically modified samples

• Biochemical approaches:

  • Perform peptide competition assays with the immunizing peptide

  • Use multiple antibodies against different NuMA epitopes and compare results

  • Verify molecular weight of detected protein bands by Western blotting

• Immunodepletion:

  • Pre-adsorb antibody with recombinant NuMA protein

  • Confirm elimination of specific signal

• Validation reporting:

  • Document validation methods used

  • Reference previous validation studies